We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Thermo Fisher Scientific's third-quarter profit declined and revenue missed estimates as its two biggest divisions struggled.

Thermo Fisher Scientific Inc.'s Q3 results demonstrated some end-market stability, particularly in the life science market.

Thermo Fisher Scientific on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this ...

Thermo Fisher boosted the lower end of its forecast for adjusted 2024 earnings, now anticipating net profit in a range between $21.35 and $22.07 a share, compared with the prior target of ...

Thermo Fisher has outperformed the market with a ... The need for products that can aid further scientific advancement will be necessary to meet this need, which is a major reason governments ...

The fetal abnormality test measures the most common chromosomal abnormalities, including Down syndrome, via a single-tube PCR process.

Boston Scientific Corp., one of the largest medical device firms in Massachusetts, reported a larger-than-expected increase in its third-quarter net sales on Thursday, but investors pulled back due to ...

Michael Ryskin, an analyst from Bank of America Securities, reiterated the Buy rating on Thermo Fisher (TMO – Research Report). The ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report) ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...